E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients aged 18 and older suffering from actinic keratoses. Patients to be considered have at least four and up to ten actinic keratoses of grade I to grade II in two treatment blocks of 25 cm2 each within the face/forehead (excluding eyelids, lips and mucosa) or bald scalp. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000614 |
E.1.2 | Term | Actinic keratosis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary study objectives are to compare the efficacy of 5% diclofenac gel twice daily to Solaraze® 3% gel twice daily, assessed by histology (according to Röwert-Huber, 2007) to evaluate the clearance of one pre-selected target lesion at 30 days post-treatment (PT, Visit 8), and assessed by actinic keratosis lesion count (using the target lesion number score (TLNS)) to evaluate the complete clinical clearance (indicated by TLNS = 0) of all target lesions in the treatment area at 30 days PT (Visit 8). |
|
E.2.2 | Secondary objectives of the trial |
A secondary study objective is to compare the efficacy of 5% diclofenac gel once daily to Solaraze® 3% gel twice daily, measured by the same primary efficacy variables, as stated for the primary objectives. A further secondary objective is to compare the efficacy of 5% diclofenac gel twice daily to Solaraze® 3% gel twice daily with regard to a decreased time to complete clinical clearance, assessed by actinic keratosis lesion count (TLNS) to evaluate the complete clinical clearance (indicated by TLNS = 0) at each visit during the treatment (Visit 3 - Visit 7) following Baseline (Visit 2).
Further secondary objectives are to assess the safety and tolerability of 5% diclofenac gel, either applied once daily or twice daily compared to Solaraze® 3% applied twice daily. Patient's compliance will also be controlled.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- caucasian male and female patients prepared and able to give written informed consent - physical ability to comply to the study preparations correctly and to follow the study restrictions and visits - ages eligible for study: 18 years and older - Actinic keratoses (AK) with a diameter of 0,5 to 1.5 cm, that are definitively distinguished from other lesions and display a minimum distance of 1 cm to neighbored lesions. The AK lesions to be treated, at least four but not more than 10, need to be of mild to moderate intensity (grade I to grade II) and located in overall two treatment blocks with a size 25 cm2 each, within the face/forehead (excluding eyelids, lips and mucosa) or bald scalp. For histological confirmation (of clearance) of the AK diagnosis a pre- and post-treatment punch biopsy is taken. - women of childbearing potential will not be considered unless they use a highly effective method of contraception (failure rate of less than 1% per year) |
|
E.4 | Principal exclusion criteria |
- Have known hypersensitivity, intolerance or allergies against diclofenac sodium or other ingredients of the investigational medicinalproducts and other non-steroidal antirheumatic agents. - Have a history of bronchospasm, asthma, urticaria, or rhinitis after the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Have a history of gastrointestinal bleeding or perforation associated with prior therapy with NSAIDs. - Have evidence of clinically significant or unstable medical conditions such as: (a) metastatic tumor or tumor with high probability of metastatic spread, (b) heart failure (NYHA class III or higher), (c) immunosuppressive disorder (e.g. HIV), (d) hematologic, hepatic, renal, neurologic or endocrine disorder, (e) collagen-vascular disorder (e.g. cerebro-vascular disorder or other bleedings), (f) gastrointestinal disorder (e.g. active ulcera or history of recurrent peptic ulcera or hemorrhage). - Within the treatment areas other malignant or benign skin tumors, Cornu cutaneum and/or hypertrophic AK lesions are observed. - Any clinically relevant abnormal finding regarding the laboratory assessment performed at Screening (only applicable for two study centers; to be reviewed at baseline). - Suffer from paresthesia in the treatment areas. - Within 6 weeks prior to Day 1 and throughout the study topical treatment in the target area(s) with topical preparations containing retinoids, steroids, 5-fluorouracil or topical immunomodulators. - Within 6 weeks prior to Day 1 and throughout the study, topical treatment in the target area(s) with diclofenac preparations other than the investigational medicinal product(s) (IMPs). - Throughout the study, topical treatments with diclofenac preparations outside the target area are prohibited. Exception: if needed only occasionally and not as permanent therapy (pro re nata, ≤ 3 days at a strech; e.g. Voltaren® Emulgel). - Within 6 weeks prior to Day 1 and throughout the study, systemic treatment with diclofenac. - Within 6 months prior to Day 1 and throughout the study, systemic treatment with retinoids, interferon, cytotoxic drugs. - Within 3 months prior to Day 1 and throughout the study, systemic treatment with 5-fluorouracil preparations, drugs known to have major organ toxicity and immunomodulators or immunosuppressive therapies. - Within 4 weeks prior to Day 1 and throughout the study, systemic treatment with oral, injectable corticosteroids. The same applies for inhaled corticosteroids, if the daily dose for beclomethasone exceeds 1200 µg/day or 600 µg/day for fluticasone. - Physical treatments in the treatment areas such as surgical excision (except biopsy for diagnostic confirmation), cryo-, thermo- or chemodestruction and photodynamic therapy within 6 weeks prior to Day 1 and throughout the study. - Curettage in the treatment areas within 4 weeks prior to Day 1 and throughout the study. - Patients who need a permanent therapy with any other NSAID. The use of NSAIDs as “prn” (pro re nata), i.e. to be taken as needed (≤ 3 days at a stretch) and the use of ASA as anticoagulative therapy (see below) will be allowed. - Patients taking methotrexate or sulfonylurea. - Anticoagulative therapy with Marcumar throughout the study. Treatment with ASA at a dose not exceeding 100 mg/d and clopidogrel at a dose not exceeding 75 mg/d will be allowed. - Patients having any significant physical abnormalities in the potential treatment areas that may cause difficulty with examination or final evaluation. - Patients not willing to abstain from sunbathing (including solarium) or any outdoor activities with intensive sun exposure without taking appropriate measures to cover the treatment areas during the study. - Are not willing to stop the use of sunscreens and make-ups in the treatment areas approximately 48 hours before a study visit with lesion count. - Patients not willing to stop using skin care products (e.g. topical treatments with anti-aging products, vitamin A, vitamin C, and/or vitamin E containing ointments and gels, and green tea preparations), except sunscreens and make-ups during the study within the treatment area. - Have any dermatological disease in the treatment areas or surrounding area that may be exacerbated by treatment with topical diclofenac or cause difficulty with examination (e.g. psoriasis, eczema, dermatitis exfoliativa). - Pregnant or breast-feeding. - Are currently or within the past 8 weeks participating in another clinical study - Any suspicion of current drug and/or alcohol abuse - Patient is institutionalized because of legal or regulatory order. - Employee of the study site or of the Sponsor’s company. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary study objective to compare the efficacy of 5% diclofenac gel twice daily to Solaraze® 3% gel twice daily, measured by complete clinical clearance (indicated by Total Lesion Number Score = 0) as well as by histological clearance of one pre-selected target lesion at 30 days PT. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |